BBHC
MURA

Brown Brothers Harriman & Co’s Mural Oncology MURA Stock Holding History

Brown Brothers Harriman & Co’s Portfolio MURA Stock Details MURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$314 – 1462
2024
Q2 		$314 Buy
+100
New +$369 ﹤0.01% 1124

Other funds holding MURA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Brown Brothers Harriman & Co's MURA Position: Q3 2024 in Review

Brown Brothers Harriman & Co sold out of Mural Oncology (MURA) in Q3 2024, closing a stake of 100 shares — an estimated $314 sold.

Brown Brothers Harriman & Co first reported a position in MURA in Q2 2024 and held it in 1 quarter. The position peaked at $314 in Q2 2024. 74 funds tracked by Wall St. Rank hold MURA as of Q3 2024.

  • Brown Brothers Harriman & Co reported no remaining Mural Oncology position as of Q3 2024 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 100 Mural Oncology shares in Q3 2024, an estimated $314.
  • Brown Brothers Harriman & Co first reported a position in Mural Oncology in Q2 2024 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Mural Oncology position peaked at $314 in Q2 2024.
  • 74 funds tracked by Wall St. Rank held Mural Oncology as of Q3 2024.

Based on Brown Brothers Harriman & Co's 13F filing for Q3 2024, filed 13 Nov 2024.